Interferon-gamma-inducing factor gene transfection into Lewis lung carcinoma cells reduces tumorigenicity in vivo

Jpn J Cancer Res. 1997 May;88(5):501-5. doi: 10.1111/j.1349-7006.1997.tb00409.x.

Abstract

To investigate the immunoregulatory effect of murine interferon-gamma-inducing factor (mIGIF), we transfected Lewis lung carcinoma (LLC) cells with a mammalian expression vector containing the mIGIF complementary DNA. The culture medium of the transfectant cells stimulated interferon-gamma (IFN-gamma) production by spleen cells in vitro in the presence of anti-CD3 antibody and markedly potentiated the effect of interleukin-12 (IL-12) on IFN-gamma production by spleen cells. mIGIF transfectant cells showed reduction of tumorigenicity and induction of an in vivo immuno-protective effect against the parental LLC cells. To examine the combined effect of systemic administration of recombinant IL-12 (rIL-12) and local mIGIF on the tumorigenicity, mice were challenged with LLC or transfectant cells on day 0, and the tumor-bearing mice were injected with 50 ng of rIL-12 intraperitoneally from day 7 to 11. Systemic rIL-12 showed an anti-tumor effect. However, mIGIF gene expression did not potentiate this effect of systemic rIL-12 in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinoma, Lewis Lung / immunology*
  • Carcinoma, Lewis Lung / prevention & control
  • Cells, Cultured
  • Cytokines / genetics*
  • Cytokines / immunology*
  • DNA, Complementary
  • Drug Interactions
  • Immunization
  • Interferon Inducers*
  • Interleukin-12 / immunology
  • Interleukin-12 / pharmacology
  • Interleukin-18
  • Mice
  • Mice, Inbred C57BL
  • Recombinant Proteins / pharmacology
  • Spleen / metabolism
  • Transfection*

Substances

  • Cytokines
  • DNA, Complementary
  • Interferon Inducers
  • Interleukin-18
  • Recombinant Proteins
  • Interleukin-12